| abstract |
A 1: 1: 1 aprepitant L-proline H 2 O composition and a 1: 1: 1 aprepitant L-proline H 2 O cocrystal are disclosed, as well as a 1: 1: 1 aprepitant L-proline H 2 O compositions or co-crystals and pharmaceutical compositions containing a pharmaceutically acceptable carrier are disclosed. The 1: 1: 1 aprepitant L-proline H 2 O composition or co-crystal can be used to treat or prevent vomiting, neuropsychiatric diseases, inflammatory diseases, pain, cancer, skin diseases, itching, respiratory diseases, or disorders associated with addiction. Can be used in the same manner as aprepitant. |